Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection

Authors

Kedar N Patel, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

11-2022

Volume

140

Issue

1

First Page

2411

Last Page

2413

Published In/Presented At

https://doi.org/10.1182/blood-2022-165452

Disciplines

Medical Education | Medicine and Health Sciences

Department(s)

USF-LVHN SELECT Program, USF-LVHN SELECT Program Students

Document Type

Article